MEN1611, a PI3K inhibitor, combined with trastuzumab (T) +/- fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01)

Simple item page
dc.conference.dateSEP 16-21, 2021
dc.conference.titleCongress of the European-Society-for-Medical-Oncology (ESMO)
dc.contributor.authorPiccart, M.
dc.contributor.authorBorrego, M. Ruiz
dc.contributor.authorArkenau, H-T.
dc.contributor.authorEscriva-De-Romani, S. I.
dc.contributor.authorHowell, S. J.
dc.contributor.authorHennequin, A.
dc.contributor.authorJimenez-Rodriguez, B.
dc.contributor.authorDel Conte, G.
dc.contributor.authorSimonelli, M.
dc.contributor.authorPalleschi, M.
dc.contributor.authorDuhoux, F.
dc.contributor.authorDe Speville Uribe, B. Doger
dc.contributor.authorCurigliano, G.
dc.contributor.authorWaters, S.
dc.contributor.authorAftimos, P. G.
dc.contributor.authorWildiers, H.
dc.contributor.authorTosi, D.
dc.contributor.authorAmair-Pinedo, F.
dc.contributor.authorPellacani, A. U. E.
dc.contributor.authorLaurent, D. O.
dc.contributor.authoraffiliation[Piccart, M.] Inst Jules Bordet, Med Oncol Clin, Brussels, Belgium
dc.contributor.authoraffiliation[Aftimos, P. G.] Inst Jules Bordet, Med Oncol Clin, Brussels, Belgium
dc.contributor.authoraffiliation[Borrego, M. Ruiz] Hosp Univ Virgen Rocio, Oncol Serv, Seville, Spain
dc.contributor.authoraffiliation[Arkenau, H-T.] Sarah Cannon Res Inst SCRI UK, SCRI, London, England
dc.contributor.authoraffiliation[Escriva-De-Romani, S. I.] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
dc.contributor.authoraffiliation[Howell, S. J.] Christie NHS Fdn Trust, Dept Oncol, Manchester, Lancs, England
dc.contributor.authoraffiliation[Hennequin, A.] Ctr Georges Francois Leclerc, Unite Phase 1, Dijon, France
dc.contributor.authoraffiliation[Jimenez-Rodriguez, B.] Hosp Clin Univ Virgen Victoria, Oncol Serv, Malaga, Spain
dc.contributor.authoraffiliation[Del Conte, G.] Osped San Raffaele, UO Oncol Med, Milan, Italy
dc.contributor.authoraffiliation[Simonelli, M.] Ist Clinico Humanitas, UO Oncol Med Ematol, Rozzano, Italy
dc.contributor.authoraffiliation[Palleschi, M.] IRCCS Ist Romagnolo Tumori IRST Dino Amadori, Oncol, Meldola, Italy
dc.contributor.authoraffiliation[Duhoux, F.] Clin Univ St Luc UCLouvain St Luc, Med Oncol Dept, Woluwe St Lambert, Belgium
dc.contributor.authoraffiliation[De Speville Uribe, B. Doger] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD Oncol Phase, Madrid, Spain
dc.contributor.authoraffiliation[Curigliano, G.] IEO Ist Europeo Oncol, Div Oncol Med, Milan, Italy
dc.contributor.authoraffiliation[Waters, S.] Velindre Canc Ctr, Trials Unit, Cardiff, S Glam, Wales
dc.contributor.authoraffiliation[Wildiers, H.] UZ Leuven, PARENT, Leuven, Belgium
dc.contributor.authoraffiliation[Tosi, D.] ICM Reg Canc Inst Montpellier, Serv Oncol Reg Med, Montpellier, France
dc.contributor.authoraffiliation[Amair-Pinedo, F.] Menarini Ric SpA, Oncol Therapeut Area, Florence, Italy
dc.contributor.authoraffiliation[Pellacani, A. U. E.] Menarini Ric SpA, R&D, Florence, Italy
dc.contributor.authoraffiliation[Laurent, D. O.] Berlin Chem AG Menarini Ric SpA, Oncol Therapeut Area, Berlin, Germany
dc.contributor.funderMenarini Ricerche S.p.A.
dc.date.accessioned2025-01-07T15:23:27Z
dc.date.available2025-01-07T15:23:27Z
dc.date.issued2021-09-21
dc.identifier.doi10.1016/j.annonc.2021.08.549
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.annonc.2021.08.549
dc.identifier.urihttps://hdl.handle.net/10668/27098
dc.identifier.wosID700527700245
dc.issue.number5
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS478-S479
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleMEN1611, a PI3K inhibitor, combined with trastuzumab (T) +/- fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01)
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number32
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen de la Victoria
SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía